GSK fights patent office again

Once again, GlaxoSmithKline is charging into patent court on Big Pharma's behalf. The drugmaker is playing point against some procedural changes the U.S. Patent and Trademark Office proposed last year; GSK already got a district judge to throw out the rules, but now the issue is up for appeal.

Designed to clear up a backlog at the patent office--a whopping 700,000-application backlog, in fact--the rules would reduce the number of ways patents can be defined and cut the number of times they can be amended. GSK and other drugmakers say the rules would erode their ability to protect their discoveries, and thus would discourage innovation. Other companies have weighed in on the same side, including agricultural giant Monsanto and General Electric.

If GSK prevails once again, Congress would have to intervene to make the changes the PTO wants.

- read the WSJ Health Blog item

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.